Form 4: IRADIMED CFO Exercises Stock Units, Sells for Tax

IRADIMED's Chief Financial Officer, John Glenn, exercised restricted stock units and performance-based restricted stock units on December 7, 2025, subsequently selling shares to cover tax obligations.

Summary

• John Glenn, Chief Financial Officer of IRADIMED CORP (IRMD), reported transactions on December 7, 2025.
• Exercised 10,504 Restricted Stock Units (RSUs), which converted into common stock on a one-for-one basis.
• Exercised 21,008 Performance-based Restricted Stock Units (PRSUs), which also converted into common stock.
• Disposed of 3,383 shares of common stock at a price of $94.57 per share to satisfy tax withholding obligations related to the RSU vesting.
• Disposed of 8,267 shares of common stock at a price of $94.57 per share to satisfy tax withholding obligations related to the PRSU vesting.
• Following these transactions, John Glenn's direct beneficial ownership of IRADIMED common stock is 22,362 shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there's a sale of shares, it's for tax purposes, which is routine. The underlying event is the vesting of equity awards, including performance-based units, which implies the achievement of performance targets.

Positives

• The vesting and exercise of both Restricted Stock Units (RSUs) and Performance-based Restricted Stock Units (PRSUs) indicate the fulfillment of employment terms and, for PRSUs, the achievement of performance targets relative to a peer group.
• The PRSU vesting structure allows for up to double the nominal granted shares if performance is 120% or greater of the peer group, suggesting potential for strong company performance.

Negatives

• A total of 11,650 shares of common stock were sold to cover tax obligations, reducing the reporting person's direct beneficial ownership.

Future Outlook

This Form 4 filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction report (Form 4) and does not provide information to analyze broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transaction is a routine insider filing, indicating a change in direct beneficial ownership for the CFO due to equity award vesting and tax-related sales. It does not suggest a significant shift in management's confidence or company strategy.
• Employees: The vesting of equity awards aligns management's interests with long-term shareholder value, particularly for performance-based units.

Key Dates

Keywords

IRADIMED, IRMD, Form 4, Insider Transaction, Restricted Stock Units, Performance-based Restricted Stock Units, CFO, Stock Vesting, Equity Incentive Plan